When does the Sudeep Pharma IPO open and close?

The Sudeep Pharma IPO opens on 21 Nov and closes on 25 Nov.

Where can I check the live subscription status of the Sudeep Pharma IPO?

You can track the real-time subscription numbers using the links below: https://www.iposcanner.ai/ipo/sudeep-pharma-ipo?tab=subscription

What is the issue size of the Sudeep Pharma IPO?

The size of Sudeep Pharma IPO is Total 1,50,92,750 shares(aggregating up to ₹895 crore) : #Fresh Issue : 16,02,024 shares(aggregating up to ₹95 crore) + #OFS : 1,34,90,726 shares(aggregating up to ₹800 crore).

What is the price band of the Sudeep Pharma IPO?

The Sudeep Pharma IPO price band is set between ₹563-593 per equity share.

What is the minimum investment for the Sudeep Pharma IPO?

The minimum investment for the Sudeep Pharma IPO is ₹14825.

What is the allotment date of the Sudeep Pharma IPO?

The share allotment date of Sudeep Pharma IPO is 26 Nov.

What is the Sudeep Pharma IPO listing date?

The Sudeep Pharma IPO will be listed on 28 Nov.

How to check Sudeep Pharma IPO allotment status online?

Follow the steps to check the Sudeep Pharma IPO allotment status online here: https://www.iposcanner.ai/ipo/sudeep-pharma-ipo?tab=allotment

Who is the registrar for the Sudeep Pharma IPO?

The registrar for the Sudeep Pharma IPO is MUFG Intime India Pvt Ltd. You can check your allotment status on their official website.

Sudeep Pharma

Open Date

21 Nov 2025

Close Date

25 Nov 2025

listed

Min Investment

₹14825

Lot Size

25 Shares

Issue Size

₹895 Cr

Price Range

₹563 - ₹593

Listing Date

Nov 28, 2025

IPO Doc

RHP PDF

About Sudeep Pharma

.read-more-text__content { display: block !important; overflow: visible !important; -webkit-line-clamp: unset !important; -webkit-box-orient: initial !important; } .read-more-text__toggle { display: none !important; }

Incorporated in 1989, Sudeep Pharma Limited is a manufacturer of pharmaceutical excipients, food-grade minerals, and specialty nutrition ingredients serving over 100 countries.It has six manufacturing facilities that have a combined production capacity of 50,000 MT, manufacturing minerals such as calcium, iron, magnesium, zinc, potassium, and sodium.The company supplies over 200 products to a wide customer base across the pharma, food, and nutrition sectors.The company has strong R&D capabilities comprising in-house labs and pilot-scale facilities for mineral salts and excipients.Product Portfolio:Pharmaceutical, Food and Nutrition BusinessSpecialty Ingredients BusinessTriturates As of 31 December 2024, the company had 704 permanent employees.

Checklist Quality Analysis

Revenue Growth

Company Valuation

Earning Expansion

The investment checklist helps you understand a company's financial health at a glance and identify quality investment opportunities easily.

₹112.5(+18.55%)GMP

18.97%Prediction Listing Gain

Sudeep Pharma IPO - Issue Objectives

₹75.81 crore will be used for machinery procurement (capex) at the Nandesari Facility. Part of the IPO proceeds will be used for general corporate purposes.

Capital expenditure

79.7%

General corporate purposes

20.3%

Capital expenditure

₹75.81 crore will be used for machinery procurement (capex) at the Nandesari Facility.

79.70%

General corporate purposes

Part of the IPO proceeds will be used for general corporate purposes.

20.30%

IPO Subscription Status

Retails

15.18x

QIB

89.78x

NII

115.36x

Financials of Sudeep Pharma

In Cr.

Revenue: ₹130.08

EBITDA: ₹48.57

Profit: ₹31.27

Total Income

EBITDA

Total Profit

Negative Value

Key Performance Indicator	30-Jun-25 (In Cr.)	31-Mar-25 (In Cr.)	31-Mar-24 (In Cr.)	31-Mar-23 (In Cr.)
Revenue	130.08	511.33	465.38	438.26
EBITDA	48.57	199.28	187.76	98.64
Expenses
Profit After Tax	31.27	138.69	133.15	62.32
Assets	922.26	717.17	513.87	420.11
Net Worth	688.32	497.53	359.07	226.29
Reserves	668.52	481.11	354.59	221.88
Borrowing	135.97	135.25	75.03	82.26

Sudeep Pharma - Promoter(s)

Sudeep Pharma

Sujit Jaysukh Bhayani

Avani Sujit Bhayani

Shanil Sujit Bhayani

Sujeet Jaysukh Bhayani

Pre Issue Share Holding

N/A

Post Issue Share Holding

N/A

About Strength & Risks

Strengths4Risks4

Why this IPO looks interesting

Key positives investors may want to consider before applying.

Market leadership and diversified product portfolio

The company is a leading manufacturer of pharmaceutical, food, nutrition, and speciality ingredients in terms of production volume as of June 30, 2025, with a strong focus on mineral-based products and iron phosphate. It has a diversified portfolio of 100+ products, supported by a stable revenue mix where pharma/food/nutrition contributed 66.43% and speciality ingredients 33.57% in Q1FY26.

Long-standing global customer base

As of June 30, 2025, the company has served 1,100+ customers, including 40+ blue-chip MNCs and 14 Fortune 500 clients, demonstrating strong global acceptance. Key customers include Pfizer, Merck, Danone, Intas, and Aurobindo. The top five customers contributed 34.08% of revenue as of June 2025, with an average relationship tenure of 7.08 years, indicating high stickiness.

Well-equipped manufacturing facilities

The company operates four manufacturing facilities, including one in Ireland, with a combined annual production capacity of 72,246 MT across 12 lines. Facilities hold 35 global accreditations, including USFDA, EXCiPACT, WHO-GMP, and ISO certifications. Notably, its Nandesari Facility I became the first and only Indian company certified by the USFDA for mineral-based food ingredients. Ongoing capex of ₹12.95 crore and the upcoming 51,200 MT facility by Q4FY26 provide clear visibility for capacity-driven growth.

Strong R&D capabilities

With two dedicated R&D centres and a team of 41 specialists, the company has executed 420+ R&D projects over the last 3 years, commercialising 127 products, including Lipoboost (liposomal ingredients) and Novelcap (encapsulated ingredients). R&D spending has scaled to ₹10.04 crore in FY25 and ₹2.67 crore (2.06% of revenue as of June 2025), reflecting sustained focus on formulation enhancement, particle engineering, improved bioavailability, and targeted release.

Contact Details

Sudeep Pharma

129/1/A, GIDC Estate, Nandesari, Vadodara, Gujarat, 391340

+912652840656

[email protected]

https://www.sudeeppharma.com/

Registrar Contact Details

MUFG Intime India Pvt Ltd

+91-22-4918 6270

[email protected]

https://in.mpms.mufg.com/Initial_Offer/public-issues.html

Sudeep Pharma IPO - FAQs

Sudeep Pharma IPO is a Mainboard IPO. The issue is priced at ₹563-593 per equity share. The minimum order quantity is 25 Shares. The IPO opens on 21 Nov, and closes on 25 Nov. MUFG Intime India Pvt Ltd is the registrar for the IPO. The shares are proposed to be listed on BSE, NSE.

Live IPOs

CMR Green Technologies

Mainboard

BSE

NSE

Open Close3rd Jun 2026 - 5th Jun 2026

Issue Size630.88 Cr

Min. Qty78 Shares

Issue Price₹ 182.00

Live IPO

Vahh Chemicals

SME

Open Close4th Jun 2026 - 8th Jun 2026

Issue Size13.45 Cr

Min. Qty2000 Shares

Issue Price₹ 60.00

Live IPO

UHM Vacation

SME

Open Close4th Jun 2026 - 8th Jun 2026

Issue Size36.02 Cr

Min. Qty800 Shares

Issue Price₹ 166.00

Live IPO

Hexagon Nutrition

Mainboard

Open Close5th Jun 2026 - 9th Jun 2026

Issue Size138.87 Cr

Min. Qty333 Shares

Issue Price₹ 42.00

Live IPO

Companies Name	Open - Close	Issue Size	Min. Qty	Issue Price
CMR Green Technologies Mainboard BSE NSE	3rd Jun 2026 - 5th Jun 2026	630.88 Cr	78 Shares	₹ 182.00
Vahh Chemicals SME	4th Jun 2026 - 8th Jun 2026	13.45 Cr	2000 Shares	₹ 60.00
UHM Vacation SME	4th Jun 2026 - 8th Jun 2026	36.02 Cr	800 Shares	₹ 166.00
Hexagon Nutrition Mainboard	5th Jun 2026 - 9th Jun 2026	138.87 Cr	333 Shares	₹ 42.00

See All Live IPOs

Sudeep Pharma

About Sudeep Pharma

Checklist Quality Analysis